http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 11:49:22 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/QIAGEN+engages+advisors+to+review+strategic+alternatives/26089739.html <p>QIAGEN N.V. (NYSE: QGEN) is working with investment banks Moelis & Company and Goldman Sachs to review strategic alternatives, according to CEO Thierry Bernard.</p><p>Bernard disclosed the company's engagement with the financial advisors during remarks at the TD Healthcare Conference. The CEO stated that QIAGEN is "very open to engage" on the strategic review process.</p><p>"We are convinced we need to review strategic alternatives," Bernard said during the conference.</p><p>The Netherlands-based molecular diagnostics company has not specified what strategic options are under consideration or provided a timeline for the review process.</p><p>QIAGEN develops and manufactures technologies for molecular testing, including sample preparation and assay http://www.streetinsider.com/Corporate+News/QIAGEN+engages+advisors+to+review+strategic+alternatives/26089739.html Mon, 02 Mar 2026 11:49:22 -0500 QGEN http://www.streetinsider.com/Mergers+and+Acquisitions/QIAGEN+engages+advisors+to+review+strategic+alternatives/26089739.html <p>QIAGEN N.V. (NYSE: QGEN) is working with investment banks Moelis & Company and Goldman Sachs to review strategic alternatives, according to CEO Thierry Bernard.</p><p>Bernard disclosed the company's engagement with the financial advisors during remarks at the TD Healthcare Conference. The CEO stated that QIAGEN is "very open to engage" on the strategic review process.</p><p>"We are convinced we need to review strategic alternatives," Bernard said during the conference.</p><p>The Netherlands-based molecular diagnostics company has not specified what strategic options are under consideration or provided a timeline for the review process.</p><p>QIAGEN develops and manufactures technologies for molecular testing, including sample preparation and assay http://www.streetinsider.com/Mergers+and+Acquisitions/QIAGEN+engages+advisors+to+review+strategic+alternatives/26089739.html Mon, 02 Mar 2026 11:49:22 -0500 QGEN http://www.streetinsider.com/Trader+Talk/QIAGEN+engages+advisors+to+review+strategic+alternatives/26089739.html <p>QIAGEN N.V. (NYSE: QGEN) is working with investment banks Moelis & Company and Goldman Sachs to review strategic alternatives, according to CEO Thierry Bernard.</p><p>Bernard disclosed the company's engagement with the financial advisors during remarks at the TD Healthcare Conference. The CEO stated that QIAGEN is "very open to engage" on the strategic review process.</p><p>"We are convinced we need to review strategic alternatives," Bernard said during the conference.</p><p>The Netherlands-based molecular diagnostics company has not specified what strategic options are under consideration or provided a timeline for the review process.</p><p>QIAGEN develops and manufactures technologies for molecular testing, including sample preparation and assay http://www.streetinsider.com/Trader+Talk/QIAGEN+engages+advisors+to+review+strategic+alternatives/26089739.html Mon, 02 Mar 2026 11:49:22 -0500 QGEN http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 -0500 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/25973728.html si-local-file:///var/storage/secattach/20260210/25973728.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/25973728.html Tue, 10 Feb 2026 11:24:00 -0500 O.00543542 QGEN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/25973728.html si-local-file:///var/storage/secattach/20260210/25973728.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/25973728.html Tue, 10 Feb 2026 11:24:00 -0500 O.00543542 QGEN http://www.streetinsider.com/Analyst+PT+Change/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2452+at+UBS/25965842.html UBS analyst Dan Leonard raised the price target on Qiagen NV (NYSE: QGEN) to $52.00 (from $50.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2452+at+UBS/25965842.html Mon, 09 Feb 2026 09:15:06 -0500 QGEN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./25960023.html si-local-file:///var/storage/secattach/20260206/25960023.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./25960023.html Fri, 06 Feb 2026 12:09:00 -0500 O.00543542 QGEN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./25960023.html si-local-file:///var/storage/secattach/20260206/25960023.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++QIAGEN+N.V.++++++++++++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./25960023.html Fri, 06 Feb 2026 12:09:00 -0500 O.00543542 QGEN http://www.streetinsider.com/Analyst+PT+Change/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2450+at+Stifel/25957977.html (Updated - February 6, 2026 9:57 AM EST) <p>Stifel analyst Daniel Arias raised the price target on Qiagen NV (NYSE: QGEN) to $50.00 (from $45.00) while maintaining a Hold rating.</p><p>The analyst commented, "QGEN closed out the year with a modestly positive 4Q, and put forth an outlook that involves quite a few moving parts when it comes to first half vs. second half dynamics and portfolio additions and subtractions. The net effect is a below consensus 1Q guide (though the Street's contemplation of NeuMoDx and Dialunox removal may not have been thorough) and a full year outlook that has back-half acceleration http://www.streetinsider.com/Analyst+PT+Change/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2450+at+Stifel/25957977.html Fri, 06 Feb 2026 09:57:20 -0500 QGEN http://www.streetinsider.com/Analyst+Comments/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2450+at+Stifel/25957977.html (Updated - February 6, 2026 9:57 AM EST) <p>Stifel analyst Daniel Arias raised the price target on Qiagen NV (NYSE: QGEN) to $50.00 (from $45.00) while maintaining a Hold rating.</p><p>The analyst commented, "QGEN closed out the year with a modestly positive 4Q, and put forth an outlook that involves quite a few moving parts when it comes to first half vs. second half dynamics and portfolio additions and subtractions. The net effect is a below consensus 1Q guide (though the Street's contemplation of NeuMoDx and Dialunox removal may not have been thorough) and a full year outlook that has back-half acceleration http://www.streetinsider.com/Analyst+Comments/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2450+at+Stifel/25957977.html Fri, 06 Feb 2026 09:57:20 -0500 QGEN http://www.streetinsider.com/Analyst+PT+Change/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2453+at+Baird/25959076.html Baird analyst Catherine Schulte raised the price target on Qiagen NV (NYSE: QGEN) to $53.00 (from $46.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Qiagen+NV+%28QGEN%29+PT+Raised+to+%2453+at+Baird/25959076.html Fri, 06 Feb 2026 09:21:22 -0500 QGEN